Elixir Medical Corporation

Print Article


Elixir Medical to Present at J.P. Morgan Healthcare Conference

Initial Clinical Findings to be presented at TCT 2011 Satellite Symposium

Sunnyvale, CA — January 4, 2012—Elixir Medical Corporation (“Elixir”), a privately held medical company, announced today that Motasim Sirhan, President and Chief Executive Officer, will present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, California. The presentation will be held on Monday, January 9, 2012 at 8:30 a.m. PST (11:30 a.m. EST) at the Westin St. Francis.


About Elixir Medical

Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions. Elixir utilizes the powerful macrocyclic lactone class of drugs, which have established safety and efficacy profiles, including Novolimus, an internally-developed mTOR inhibitor and metabolite of Sirolimus, as well as Myolimus, licensed from Novartis Pharma AG for site specific drug delivery applications. 

The Company has a broad portfolio of coronary vascular therapy products leveraging Elixir’s unique pharmaceuticals, drug release technologies, stent platforms, and bioresorbable scaffold systems.  In 2012, Elixir will be entering the coronary stent market with the CE Mark approved DESyneTM, a high performance durable polymer coated drug-eluting stent (DES). This will be followed by DESyne BDTM, a DES with a polymer that biodegrades within 6-9 months, leaving behind a bare metal stent.   Elixir’s ground-breaking fullybioresorbable vascular scaffold, DESolveTM, is currently enrolling its CE Mark pivotal trial.

Elixir is also developing a drug coated balloon for peripheral vascular therapy.  For more information, please visit www.elixirmedical.com.


Vinayak Bhat, PhD
(408) 636-2000